CRISPR Therapeutics AGCRSPNASDAQ
Loading
EBITDA as a percentage of revenue
Latest
-15636.44%
↑ 29% vs avg
Percentile
P20
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
-21916.77%
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| 2025 | -15636.44% | -1123.5% |
| 2024 | -1278.02% | -2232.8% |
| 2023 | -54.78% | +100.0% |
| 2022 | -148850.69% | -347275.8% |
| 2021 | 42.87% | +100.1% |
| 2020 | -48018.22% | -270295.2% |
| 2019 | 17.77% | +100.4% |
| 2018 | -4975.16% | -3209.9% |
| 2017 | -150.31% | +43.2% |
| 2016 | -264.68% | - |